642 EO2401 microbiome derived therapeutic vaccine + nivolumab, with/without standard continuous, or low-dose symptom directed, bevacizumab, in recurrent glioblastoma: phase 1–2 EOGBM1–18/ROSALIE study

Authors :: David Reardon
Ahmed Idbaih
Maria Vieito
Ghazaleh Tabatabai
Agostina Stradella
Francois Ghiringhelli
Michael Burger
Iris Mildenberger
Ulrich Herrlinger
Macarena González
Marta GilMartin
Mirjam Renovanz
Mehdi Touat
Patrick Wen
Antje Wick
Cecile Gouttefangeas
Ana Maia
Chistophe Bonny
Jan Fagerberg
Wolfgang Wick
Source :: Regular and Young Investigator Award Abstracts.
Publication Year :: 2022
Publisher :: BMJ Publishing Group Ltd, 2022.

Tools